Resolutions at Pharmacolog AB’s (publ) extraordinary general meeting August 24 2022

24 August 2022 - 17:18

The shareholders of Pharmacolog in Uppsala AB (publ) held the Extraordinary General Meeting on August 24, 2022 in Uppsala. (information below in Swedish only)

Stämman beslutade om nyval av Björn Varnestig som styrelseledamot för en mandattid som sträcker sig fram till slutet av nästa årsstämma.

Noterades att Olof Johansson har meddelat att han avgår som styrelseledamot i bolaget i samband med den extra bolagsstämman. Styrelsen kommer således bestå av styrelseordförande Erik Hedlund samt styrelseledamöterna Carl-Johan Spak, Ragnar Linder, och Björn Varnestig för tiden intill nästa årsstämma.

For more information contact:

Mats Högberg, CEO

Email: [email protected]
Phone: +46
70-546 50 21

About Pharmacolog AB

Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog’s products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.

The following trademarks are owned and protected by Pharmacolog i Uppsala AB: Pharmacolog™-logo, DrugLog™, WasteLog™, PrepLog™ and Pharmacolog Dashboard™.

Further information regarding the company is available at

The company's Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through [email protected].

Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
Pharmacolog i Uppsala AB
Pharmacolog i Uppsala develops systems and solutions that aim to optimize and ensure correct and effective treatment with injectable drugs. Its products include WasteLog, DrugLog, and PrepLog, which are aimed at a large number of treatment areas, such as; oncology, infectious diseases, and intensive care....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More